Meaningful change is possible when science and humanity go hand in hand
For generations, those born with Hereditary Angioedema inherited not only a rare genetic condition but a life shaped by unpredictability and fear — their futures hostage to swelling that could arrive without warning and depart without explanation. Over five decades, the work of clinicians like Dr. Konrad Bork at the University Medical Center in Mainz has helped transform HAE from an unnamed dread into a condition with known mechanisms, targeted therapies, and patients who can now dare to plan. As the world marks HAE Day on May 16, 2026, the field pauses to honor how far it has traveled — and to reckon honestly with how far it still must go.
- For decades, HAE patients endured attacks of painful, potentially fatal swelling with no diagnosis, no treatment, and no framework for understanding what was happening to their own bodies.
- The identification of C1 esterase inhibitor deficiency and the arrival of C1-INH therapy in 1979 cracked open the mystery, giving medicine its first real foothold against the disease.
- Subsequent discoveries — including a C1-INH-independent form of HAE identified in 2000 and multiple genetic variants since — revealed the condition to be far more complex, demanding ever more nuanced approaches to care.
- Modern patients can now pursue careers, build families, and live without structuring every decision around the fear of the next attack — a transformation Dr. Bork describes as not merely medical but existential.
- Yet diagnosis still arrives late for many, specialized care remains unevenly distributed across the world, and the psychological weight of living with a rare, unpredictable disease cannot be lifted by medication alone.
- The path forward, Bork argues, runs through education, patient community, and the kind of empathetic listening that reminds clinicians what scientific progress is ultimately for.
Dr. Konrad Bork has spent his career at the University Medical Center in Mainz watching Hereditary Angioedema change — first as a clinical mystery, then as a diagnosable condition, and finally as something patients can genuinely manage. HAE is a rare genetic disorder that causes sudden, severe swelling in the face, throat, abdomen, and elsewhere. It is unpredictable, painful, and at times life-threatening. As HAE Day on May 16 approaches, Bork has been reflecting on both the distance traveled and the distance that remains.
When he began his work, diagnosis took years and effective treatment did not exist. Patients lived in sustained fear, with little explanation and less support. The field shifted when C1 esterase inhibitor deficiency was identified as the underlying cause, and in 1979 the introduction of C1-INH therapy gave doctors their first means of intervening at the source rather than simply managing symptoms. Then in 2000, researchers identified a form of HAE that did not involve C1-INH deficiency at all, revealing that the disease was more genetically varied — and more complex — than anyone had assumed.
These advances have changed what is possible for patients in ways that go beyond the clinical. Bork has watched people who once organized their entire lives around the fear of an attack begin to pursue education, build careers, and start families. The transformation, he says, is existential. But he is careful not to declare victory. Many patients still wait years for a correct diagnosis. Access to specialized care is unequal across regions. And the psychological burden of living with a rare, unpredictable condition is not something any medication can fully resolve.
Bork has come to measure treatment success not only in reduced attacks but in the confidence and independence patients reclaim. He credits patients themselves with teaching him this. His broader message — to younger physicians and to the field — is that meaningful progress in rare disease emerges when scientific rigor and human empathy are held together: listening carefully, staying curious, and never losing sight of the life being lived on the other side of the diagnosis.
Dr. Konrad Bork has spent decades watching a disease transform from medical mystery into something manageable—and in doing so, he has watched the lives of his patients transform as well. A dermatologist at the University Medical Center in Mainz, Germany, Bork specializes in Hereditary Angioedema, a rare genetic condition that strikes without warning, causing swelling in the face, throat, abdomen, and other parts of the body. For those who live with it, HAE is not merely uncomfortable; it is unpredictable, painful, and sometimes life-threatening. As the medical community approaches HAE Day on May 16, Bork reflected on how far the field has traveled and how much distance remains.
When Bork began his work with HAE patients, the disease was barely understood. Diagnosis took years. Effective treatment did not exist. Patients and their families endured constant uncertainty, living in fear of the next attack, with little explanation and less support. "What impressed me most," Bork recalled, "was the resilience of patients and families who lived with constant uncertainty and fear." The turning point came with the identification of C1 esterase inhibitor deficiency as the underlying cause—a moment that transformed HAE from a clinical puzzle into a disease with a clear biological mechanism. In 1979, the introduction of C1-INH therapy made it possible to intervene directly at the source of the problem. For the first time, doctors could actually treat the disease rather than simply manage its symptoms.
The field continued to evolve. In 2000, researchers identified a new form of HAE that did not involve C1-INH deficiency at all, opening the door to understanding that the disease was more complex than initially thought. Multiple genetic variants have since been discovered, each requiring different approaches to care. These advances have fundamentally altered what is possible for patients. Bork has seen people who once structured their entire lives around the fear of attack now able to pursue education, build careers, start families. The difference is not merely medical; it is existential. "When I compare that to patients decades ago, who structured their entire lives around unpredictability, it becomes very clear how transformative progress has been," he said.
Yet Bork is careful not to declare victory. Even with effective therapies now available, significant challenges persist. Early diagnosis remains difficult—many patients still wait years before receiving a correct diagnosis. Access to specialized care is unequal across regions and countries. Beyond the medical realm, patients continue to carry psychological burden, social limitations, and uncertainty that no medication alone can resolve. Bork has learned that treatment success cannot be measured only in reduced attacks; it must also account for the confidence and independence patients regain. Patients themselves have taught him this. Over decades of practice, he has been reminded repeatedly that what matters most is not just clinical outcomes but the ability to live openly and actively.
Bork believes that addressing these remaining gaps requires more than medicine. Education, trust, and community are essential. Patient organizations, family support networks, and informed healthcare professionals make a tangible difference in how well patients manage their condition and participate in their own care. The path to progress in rare diseases has never been linear. There were periods of stagnation, skepticism toward new approaches, and the inherent difficulty of conducting rigorous clinical trials in small patient populations. Yet these obstacles also fostered collaboration and persistence within the medical and patient communities. For Bork, the greatest motivation has always been witnessing patients benefit directly from new therapies—seeing scientific progress translate into improved daily life. His message to younger physicians is simple: listen to patients, remain curious, and remember that meaningful change emerges when science and human empathy work together.
Notable Quotes
Treatment success is not only measured in reduced attacks, but in regained confidence and independence— Dr. Konrad Bork
Progress in rare diseases comes from persistence, collaboration and empathy— Dr. Konrad Bork
The Hearth Conversation Another angle on the story
When you say patients decades ago structured their lives around unpredictability, what does that actually look like day to day?
It means you don't commit to anything. You don't enroll in university because you might have an attack during exams. You don't take a job that requires you to be somewhere every single day. You don't plan a wedding. You live in a kind of suspended state, waiting for the next crisis.
And now, with treatment available, that changes?
Fundamentally. A patient can say, "I'm going to medical school," or "I'm going to have children," and mean it. The attack may still come, but it's no longer the organizing principle of existence.
You mentioned that patients taught you treatment success isn't just about fewer attacks. What else matters?
Confidence. Independence. The ability to say yes to an invitation without calculating the risk. To go to work and not spend the day bracing for collapse. That's what therapy actually buys you—not just survival, but participation.
What about the patients who still can't access these treatments?
That's the hard part. We have the tools now, but they're not equally distributed. A patient in Germany has options a patient in a less resourced country may not have. And even within countries, access depends on whether your doctor knows what HAE is, whether you can reach a specialist.
So the medical problem is partly solved, but the human problem remains?
Exactly. You can give someone the best therapy in the world, but if they're isolated, if they don't understand their disease, if they carry shame or fear—the medication alone won't heal that. That's why I tell young doctors to listen first.